Item 7.01 Regulation FD Disclosure.

Beginning on January 5, 2022, members of management of VYNE Therapeutics Inc. will use the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K in connection with investor meetings.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

The following exhibit is being furnished herewith.





Exhibit No.              Description

  99.1                     Investor Presentation

                         Cover Page Interactive Data File (embedded within the
104                      Inline XBRL document)

© Edgar Online, source Glimpses